NICE to appraise cryoablation and HIFU for prostate cancer
This article was originally published in Clinica
The UK’s National Institute for Health and Clinical Excellence (NICE) is to appraise two “focal therapy” ablation technologies for the treatment of localised prostate cancer: cryoablation and high-intensity focused ultrasound (HIFU). The appraisals will take place under NICE’s interventional procedures programme, which assesses the efficacy and safety of rarely used or highly innovative techniques, with a view to increasing their use in the NHS. A provisional decision is expected to be issued for consultation in autumn 2011; the provisional publication date is end of 2011 or early-2012.